Tags : Qiagen

Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations

Shots: Qiagen’s QIAseq SARS-CoV-2 primer panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to track changes in the viral genome The two-step process uses advanced QIAseq technologies to conduct reverse transcription and cDNA synthesis from a viral RNA sample, then generate libraries compatible with Illumina sequencing platforms The solution […]Read More

Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN

Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on Mar 2, 2020, making the latest deal value as $12.5B The amendment also provides for a reduction of the minimum […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

PharmaShots Weekly Snapshot (April 13 -17, 2020)

1. Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19 Published: Apr 17, 2020 | Tags: Sinovac, Initiates, P-I, Clinical Study, Vaccine Candidate, Against, COVID-19 2. 1Health.io Launches Self-Collection Kits to Detect COVID-19 Published: Apr 16, 2020 | Tags: 1Health.io, Launches, Self-Collection Kits, Detect, COVID-19 3. Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations […]Read More

QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI

Shots: QIAGEN launches its therascreen BRAF V600E RGQ PCR Kit as a CDx to Pfizer’s Braftovi (encorafenib) in combination with Lilly’s Erbitux (cetuximab) for the treatment of patients with m-CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy The therascreen BRAF V600E kit runs on QIAGEN’s Rotor-Gene Q MDx […]Read More

PharmaShots Weekly Snapshot (March 30 – April 03, 2020)

1. Sorrento Initiates the Next Phase of its Collaboration with Celularity Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity 2.  Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic Published: Apr 03, 2020 | Tags: Celltrion, Enters, Next Phase, Development, Antiviral Therapy, Combat, COVID-19 Pandemic 3. […]Read More

QIAGEN’s QIAstat-Dx Test Kit Receives the US FDA’s EUA as

Shots: QIAGEN has received the FDA’s EUA for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for diagnosing patients infected with the novel COVID-19 The syndromic test will be deployed in pandemic and can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients showing similar symptoms. The kit requires < 1min. for […]Read More

Insights+: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

PharmaShots Weekly Snapshot (March 23-27, 2020)

1. Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic Published: Mar 26, 2020 | Tags: Mylan, Delays, Merger, Upjohn, Due, COVID-19 Pandemic 2.  Medopad Provides its Remote Patient Monitoring Platform to Support Global COVID-19 Pandemic2 Published: Mar 26, 2020 | Tags: Medopad, Provides, Remote Patient Monitoring Platform, Support, Global, COVID-19 Pandemic 3.  Quidel’s […]Read More